Association of an aurora kinase a ( AURKA ) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib

Conclusion In patients who received alisertib for advanced or metastatic urothelial carcinoma, longer progression-free survival was observed in carriers of the minor allele A of rs2273535 inAURKA than in patients who were homozygous for the major allele T. This finding, based on a small pilot trial, warrants further investigation.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research